GenSight Biologics: Progressing the ophthalmic pipeline
Paris-based biopharma GenSight Biologics SA named Mohamed Genead as Chief Medical Officer in early May. Most recently, Genead was Vice President & Global Therapeutic Area Head for Ophthalmology/Retina Gene Therapy at Biogen.
Prior to Biogen, Genead served eight years at Allergan as Executive Medical Director, Global Clinical Development for the Ophthalmology/Retina Therapeutic Area. Before this, he was the Vice President & Global Head of Clinical Development at Allegro. Genead is a board member of several ophthalmic organisations, and he has authored numerous peer-reviewed papers.
At GenSight Biologics, Genead will be responsible for setting the strategy for and execution of global clinical development programmes, management of the companys medical affairs, clinical operations and biostatistics departments. He will be based in the US.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium